Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Ryeman40on Dec 10, 2020 4:46pm
264 Views
Post# 32082025

Long term

Long term

This is one of my long term holds. I have a lot of shares and more than likely will buy more if i can. My timeline is around a year. 

There has been a few research papers from the Japanese, Korean and Chinese on the incredible benefits of H2S but they all have said more research needs to be done. Enter Antibe. 

With the adaptive phase 3 design i believe we should know after 50% of patients have completed treatment if we have an absolute winner. If Antibe doesn't need to increase sample size i think there will be a lot of attention turning Antibes way for a potential blockbuster and there's already been a few in the nsaid market. Pros for adaptive design are reduced potential cost, higher potential success  and stakeholder buy-in. 

IMHO i believe something like this comes along once in awhile and I've missed out on a few but not this time. 

<< Previous
Bullboard Posts
Next >>